Callan Family Office LLC Purchases 19,203 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Callan Family Office LLC increased its stake in Bristol Myers Squibb by 236.1% in Q2, acquiring an additional 19,203 shares, bringing its total holdings to 27,337 shares valued at approximately $1.27 million.
• The company's latest quarterly earnings exceeded expectations, with reported EPS of $1.46 against an estimate of $1.07, along with revenues of $12.27 billion beating predictions of $11.32 billion.
• Bristol Myers Squibb announced a quarterly dividend of $0.62 per share, reflecting an annualized rate of $2.48 and a yield of 5.6%, with a payout ratio currently at 100%.

Callan Family Office LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 236.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,337 shares of the biopharmaceutical company's stock after acquiring an additional 19,203 shares during the period. Callan Family Office LLC's holdings in Bristol Myers Squibb were worth $1,265,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Wellington Management Group LLP raised its stake in Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock worth $1,447,198,000 after acquiring an additional 17,750,938 shares during the period. GQG Partners LLC raised its position in shares of Bristol Myers Squibb by 22,647.6% during the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock valued at $733,310,000 after buying an additional 11,970,598 shares during the last quarter. Nuveen LLC bought a new stake in shares of Bristol Myers Squibb during the first quarter valued at approximately $624,369,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $98,898,000. Finally, Bank of New York Mellon Corp raised its position in shares of Bristol Myers Squibb by 8.6% during the first quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company's stock valued at $1,638,501,000 after buying an additional 2,131,205 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Trading Down 1.5%

Shares of BMY opened at $44.01 on Monday. The company's fifty day moving average is $46.26 and its 200 day moving average is $47.96. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The stock has a market capitalization of $89.57 billion, a PE ratio of 17.74, a P/E/G ratio of 2.26 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the previous year, the business posted $2.07 earnings per share. Bristol Myers Squibb's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BMY shares. Citigroup reduced their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Weiss Ratings reiterated a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Saturday, September 27th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. Finally, Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $57.14.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company's stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.07% of the stock is owned by insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.